Ignite Creation Date:
2024-05-05 @ 4:48 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00310895
Status:
COMPLETED
Last Update Posted:
2015-12-24
First Post:
2006-04-04
Brief Title:
Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies
Sponsor:
Geron Corporation
Organization:
Geron Corporation
Study Overview
Official Title:
A Phase I Sequential Cohort Dose Escalation Trial to Determine the Safety Tolerability and MTD of GRN163L in Patients With Refractory or Relapsed Solid Tumor Malignancies
Status:
COMPLETED
Status Verified Date:
2015-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the safety and the maximum tolerated dose of GRN163L administration in treating patients with refractory or relapsed solid tumor malignancies
Detailed Description:
GRN163L is a telomerase template antagonist with in vitro and in vivo activity in a variety of tumor model systems Telomerase is an enzyme that is active primarily in tumor cells and is crucial for the indefinite growth of tumor cells Inhibition of telomerase may result in antineoplastic effects
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None